Abraxis gets FDA approval for chemotherapy drug
Oct 17 (Reuters) - Abraxis BioScience Inc ABBI.O said U.S. health regulators approved its unit, Abraxis Pharmaceutical Products, to market chemotherapy drug Epirubicin hydrochloride injection in four dosage forms, two of which are new to market.
The company said the remaining two dosage forms are marketed by Pfizer Inc (PFE.N: Quote, Profile, Research) as Ellence.
Abraxis expects to launch Epirubicin in single dose vials in the fourth quarter. (Reporting by Ratul Ray Chaudhuri in Bangalore)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Uneasy Truce
Kung Fu finger calls it a day
